Skip to main content

Table 2 Outcomes of ROP and other outcomes in two groups

From: Effect of early prophylactic low-dose recombinant human erythropoietin on retinopathy of prematurity in very preterm infants

Outcomes

Control n = 948

rhEPO n = 950

RR (95% CI)

P value

Death, n (%)

70/948 (7.4)

38/950 (4.0)

0.9 (0.94–0.99)

0.001

ROP, n (%)

116/878 (13.2)

93/912 (10.2)

0.97 (0.93–1.00)

0.055

 Type 1 ROP, n (%)

28/878 (3.2)

23/912 (2.5)

0.99 (0.98–1.01)

0.478

 Type 2 ROP, n (%)

36/878 (4.1)

20/912 (2.2)

0.98 (0.96–1.00)

0.021

 Type 1 or Type 2 ROP, n (%)

64/878 (7.3)

43/912 (4.7)

0.97 (0.95–1.00)

0.022

Mild ROP, n (%)

52 /878(5.9)

50/912 (5.5)

1.00 (0.97–1.02)

0.760

Hospital acquired sepsis, n (%)

255 (26.9)

232 (24.4)

0.97 (0.92–1.0)

0.227

BPD, n (%)

210 (22.2)

181 (19.1)

0.96 (0.92–1.01)

0.100

NEC, n (%)

51 (5.4)

29 (3.1)

0.98 (0.96–1.00)

0.012

IVH (≥ grade 3), n (%)

72 (7.6)

37 (3.9)

0.96 (0.94–0.98)

0.001

Mechanical ventilation, d

3.3 ± 7.4

2.9 ± 5.5

0.41 (-0.39–1.23)

0.313

  1. CI, confidence interval; rhEPO, recombinant human erythropoietin; ROP, retinopathy of prematurity. BPD, bronchopulmonary dysplasia; NEC, necrotizing enterocolitis; IVH, intraventricular hemorrhage